MHC molecules (HLA)
Also known as: major histocompatibility complex, MHC, HLA, human leukocyte antigen, MHC class I, MHC class II, HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ, HLA-DP, tissue type
Highly polymorphic cell-surface glycoproteins (HLA in humans) that bind peptide fragments and display them to T cells: class I on all nucleated cells presents to CD8 T cells; class II on antigen-presenting cells presents to CD4 T cells.
Overview
The major histocompatibility complex is a cluster of genes on the short arm of chromosome 6 (6p21.3), called the human leukocyte antigen (HLA) system in humans. Its classical genes are the most polymorphic in the human genome, with thousands of alleles, and are codominantly expressed; they are inherited as linked blocks (haplotypes), one from each parent, so any sibling has a 25% chance of being an HLA-identical match. Polymorphism is concentrated in the peptide-binding groove, so different alleles present different peptide repertoires — protecting the population from pathogens that might escape presentation, but making transplantation between unrelated people difficult.
Class I molecules (HLA-A, -B, -C) consist of a polymorphic transmembrane α (heavy) chain with three domains, non-covalently associated with β2-microglobulin (encoded on chromosome 15). The α1 and α2 domains form a groove closed at both ends, binding peptides of ≈ 8–10 amino acids derived mainly from cytosolic (endogenous) proteins; the α3 domain binds CD8. Class I is expressed on all nucleated cells (and platelets, but not mature red cells) and is also the ligand for NK-cell inhibitory receptors.
Class II molecules (HLA-DP, -DQ, -DR) consist of two transmembrane chains, α and β; the α1 and β1 domains form a groove open at both ends that holds longer peptides (≈ 13–25 amino acids) from endocytosed (exogenous) proteins; the β2 domain binds CD4. Class II is expressed constitutively by professional antigen-presenting cells — dendritic cells, macrophages and B cells — and by thymic epithelium, and can be induced on other cells by IFN-γ. The class III region between them encodes non-presenting immune proteins such as complement C2, C4 and factor B, and TNF.
- Location
Class I: surface of all nucleated cells. Class II: dendritic cells, macrophages, B cells, thymic epithelium and IFN-γ-activated cells.
Parts & subdivisions
- α chain + β2-microglobulin; all nucleated cells; 8–10-mer peptides from cytosolic proteins; presents to CD8 T cells; inhibits NK cells.
- α + β chains; antigen-presenting cells; 13–25-mer peptides from endocytosed proteins; presents to CD4 T cells.
- Genes for complement components (C2, C4, factor B), TNF and heat-shock proteins.
- Non-classical moleculesHLA-E (ligand for NK receptor CD94/NKG2A), HLA-G (on trophoblast; fetal tolerance), CD1 (presents lipids) and MR1 (presents vitamin B metabolites to MAIT cells).
Function
- Display peptide fragments of cellular and ingested proteins for inspection by T cells.
- Determine MHC restriction of T cells during thymic selection.
- Regulate NK-cell activity (class I).
- Act as the main barrier to allogeneic transplantation (alloantigens).
Clinical significance
HLA matching in transplantation
Matching at HLA-A, -B and -DR improves kidney graft survival; haematopoietic stem-cell transplants require closer matching (often including -C and -DQ) to limit rejection and graft-versus-host disease. Pre-transplant cross-matching detects preformed anti-HLA antibodies that would cause hyperacute or antibody-mediated rejection.
HLA disease associations
HLA-B27: ankylosing spondylitis, reactive arthritis, psoriatic and IBD-associated arthritis, acute anterior uveitis. HLA-DQ2/DQ8: coeliac disease (> 95%). HLA-DR3/DR4: type 1 diabetes. HLA-DR4: rheumatoid arthritis. HLA-DR15 (DR2): multiple sclerosis, Goodpasture syndrome. HLA-B51: Behçet disease. Pharmacogenomic screening: HLA-B57:01 before abacavir; HLA-B15:02 before carbamazepine in South-East Asian patients.
MHC deficiency and evasion
"Bare lymphocyte syndromes": MHC class II deficiency causes CD4 lymphopenia and severe combined-type infections; class I deficiency (TAP mutations) causes chronic respiratory infections. Many viruses (CMV, HIV via Nef, adenovirus) down-regulate class I to evade CD8 T cells.
Mnemonics
Rule of 8
MHC I × CD8 = 8; MHC II × CD4 = 8.
Which HLA genes?
Class I has one letter (A, B, C); class II has two letters (DP, DQ, DR).
Test yourself
MHC class II molecules…
- Are expressed on all nucleated cells
- Present endogenous peptides to CD8 T cells
- Present exogenous peptides to CD4 T cells and are expressed mainly on antigen-presenting cells
- Consist of a heavy chain associated with β2-microglobulin
Answer: Present exogenous peptides to CD4 T cells and are expressed mainly on antigen-presenting cells
Class II (HLA-DP, -DQ, -DR; α and β chains) is expressed on dendritic cells, macrophages, B cells and thymic epithelium and presents peptides from endocytosed (exogenous) proteins to CD4 T cells. Class I (heavy chain + β2-microglobulin) is on all nucleated cells and presents to CD8 cells.
Natural killer cells kill virus-infected and tumour cells that…
- Express high levels of MHC class II
- Have lost or down-regulated MHC class I
- Are coated with IgE
- Express CD4
Answer: Have lost or down-regulated MHC class I
NK cells are held back by inhibitory receptors (KIRs, CD94/NKG2A) that recognise MHC class I. Viruses and tumours often down-regulate MHC I to evade CD8 T cells, which removes this inhibition — the "missing-self" hypothesis. NK cells also kill antibody-coated cells (ADCC via CD16).
Compiled from standard anatomy and physiology references — see the Lymphatic & Immune System sources. For education only; not medical advice.